Latest News and Press Releases

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors,...

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including...

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC (CX-2051) with...

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...